Allergan and the Saint Regis Mohawk Tribe have been refused an attempt to appeal to the US Supreme Court over a ruling that confirmed four key patents protecting the Restasis (ciclosporin) dry-eye treatment as being invalid for obviousness.
The case revolved around a ‘blocking-patent’ doctrine applied by several US district courts in multiple cases, including one involving Acorda’s...